Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 13, keine Gesamtzahl für „substrate“
Suchtreffer
Begriffe & Kennungen
Epidyolex · 4.5 · Sensitive CYP2C9 substrates Coadministration of cannabidiol (7.5 mg/kg twice daily) with a single dose of tolb
Eintrag öffnenEpidyolex · 4.5 · Sensitive P-gp substrates given orally Coadministration of cannabidiol with orally administered everolimus, a
Eintrag öffnenEpidyolex · 4.5 · Sensitive UGT1A9 substrates Coadministration of cannabidiol (7.5 mg/kg twice daily) with a single dose of myco
Eintrag öffnenEpidyolex · 4.5 · Sensitive UGT2B7 substrates Coadministration of cannabidiol (7.5 mg/kg twice daily) with a single dose of zido
Eintrag öffnenEpidyolex · 4.5 · Sensitive substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A9, and UGT2B7 Sensitive CYP1A2 substrate
Eintrag öffnenErivedge · 4.5 · Clinically significant PK interactions between vismodegib and CYP450 substrates are not expected. In vitro, CY
Eintrag öffnenEtcamah · 4.5 · 6 be avoided. All other CYP2B6 substrates are permitted but caution should be exercised and patients monitored
Eintrag öffnenEtcamah · 4.5 · BCRP sensitive substrates In vitro data show that camizestrant is an inhibitor of Breast Cancer Resistance Pro
Eintrag öffnenEtcamah · 4.5 · CYP2B6 sensitive substrates In vitro data show that camizestrant is an inhibitor of Cytochrome P450 2B6 (CYP2B
Eintrag öffnenEtcamah · 4.5 · CYP2C9 and CYP2C19 substrates In vitro data in conjunction with mechanistic static modelling show that camizes
Eintrag öffnenEtcamah · 4.5 · CYP3A4/5 substrates In a clinical study, concomitant use of camizestrant increased midazolam, a sensitive CYP3
Eintrag öffnenEtcamah · 4.5 · OATP1B1 sensitive substrates In vitro data show that camizestrant is an inhibitor of OATP1B1. Therefore, camiz
Eintrag öffnenEtcamah · 4.5 · P-gp sensitive substrates In vitro data show that camizestrant is an inhibitor of P-glycoprotein (P-gp). There
Eintrag öffnenEtcamah · 4.5 · The co-administration of camizestrant and moderately sensitive substrates of CYP2C9 (including but not limited
Eintrag öffnenEucreas · 4.5 · Drug-drug interaction studies with digoxin (P-glycoprotein substrate) and warfarin (CYP2C9 substrate) in healt
Eintrag öffnenEurartesim · 4.5 · Piperaquine has the potential to increase the rate of metabolism for CYP2E1 substrates resulting in a decrease
Eintrag öffnenEurartesim · 4.5 · Piperaquine has the potential to increase the rate of metabolism for CYP2E1 substrates resulting in a decrease
Eintrag öffnenEviplera · 4.5 · P-glycoprotein substrates Rilpivirine inhibits P-glycoprotein (P-gp) in vitro (IC50 is 9.2 µM). In a clinical
Eintrag öffnenEvotaz · 4.5 · 9 P-gp, is contraindicated. Clinically significant interactions between EVOTAZ and substrates of CYP1A2, CYP2B
Eintrag öffnenEvotaz · 4.5 · Atazanavir is metabolised in the liver through CYP3A4. Cobicistat is a CYP3A substrate and is metabolised to a
Eintrag öffnen